The present invention relates to novel formulations of soluble Fc receptors and especially to formulations containing high concentrations of soluble Fc³RIIB receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved.
